Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd R Burmester

Showing results (61-70 of 334) with videos related to

Pageof 34
Sort By:
Rheumatology International|November 12, 2018
Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in GermanyKlaus Krüger, Gerd R Burmester, Siegfried Wassenberg, et al.
Annals of the Rheumatic Diseases|July 4, 2023
Sustained responses after anti-CD38 treatment with daratumumab in two patients with refractory systemic lupus erythematosusTobias Alexander, Lennard Ostendorf, Robert Biesen, et al.
BMJ Open|June 16, 2018
Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in GermanyKlaus Krüger, Gerd R Burmester, Siegfried Wassenberg, et al.
Journal of Neuroimmunology|December 20, 2005
CD25 regulatory T cells determine secondary but not primary remission in EAE: impact on long-term disease progressionDagmar Gärtner, Holger Hoff, Ulrike Gimsa, et al.
Rheumatology (Oxford, England)|July 4, 2012
Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE studyVibeke Strand, Gerd R Burmester, Sarika Ogale, et al.
Arthritis and Rheumatism|September 30, 2008
Reactivation of rheumatoid arthritis after pregnancy: increased phagocyte and recurring lymphocyte gene activityThomas Häupl, Monika Østensen, Andreas Grützkau, et al.
Rheumatology (Oxford, England)|April 19, 2021
Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitorsRoy Fleischmann, Mark C Genovese, Karina Maslova, et al.
Annals of the Rheumatic Diseases|November 12, 2020
Publishing in 2@84Marco Lanzillotta, Chiara Crotti, Vital Manuel Da Silva Domingues, et al.
BMJ Open|March 2, 2018
Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Im<i>P</i>act of <i>R</i>esidual Inflammation Detected via Imaging T<i>E</i>chniques, <i>D</i>rug Levels and Patient Characteristics on the Outcome of Dose Taper<i>I</i>ng of Adalimumab in <i>C</i>linical Remission Rheumatoid Ar<i>T</i>hritis (<i>RA</i>) patients (PREDICTRA)Paul Emery, Gerd R Burmester, Esperanza Naredo, et al.
Annals of the Rheumatic Diseases|May 15, 2017
High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart blockAnna R Lisney, Franziska Szelinski, Karin Reiter, et al.
Pageof 34

Showing results (61-70 of 334) with videos related to

Sort By:
Pageof 34
Rheumatology International|November 12, 2018
Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in GermanyKlaus Krüger, Gerd R Burmester, Siegfried Wassenberg, et al.
Annals of the Rheumatic Diseases|July 4, 2023
Sustained responses after anti-CD38 treatment with daratumumab in two patients with refractory systemic lupus erythematosusTobias Alexander, Lennard Ostendorf, Robert Biesen, et al.
BMJ Open|June 16, 2018
Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in GermanyKlaus Krüger, Gerd R Burmester, Siegfried Wassenberg, et al.
Journal of Neuroimmunology|December 20, 2005
CD25 regulatory T cells determine secondary but not primary remission in EAE: impact on long-term disease progressionDagmar Gärtner, Holger Hoff, Ulrike Gimsa, et al.
Rheumatology (Oxford, England)|July 4, 2012
Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE studyVibeke Strand, Gerd R Burmester, Sarika Ogale, et al.
Arthritis and Rheumatism|September 30, 2008
Reactivation of rheumatoid arthritis after pregnancy: increased phagocyte and recurring lymphocyte gene activityThomas Häupl, Monika Østensen, Andreas Grützkau, et al.
Rheumatology (Oxford, England)|April 19, 2021
Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitorsRoy Fleischmann, Mark C Genovese, Karina Maslova, et al.
Annals of the Rheumatic Diseases|November 12, 2020
Publishing in 2@84Marco Lanzillotta, Chiara Crotti, Vital Manuel Da Silva Domingues, et al.
BMJ Open|March 2, 2018
Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Im<i>P</i>act of <i>R</i>esidual Inflammation Detected via Imaging T<i>E</i>chniques, <i>D</i>rug Levels and Patient Characteristics on the Outcome of Dose Taper<i>I</i>ng of Adalimumab in <i>C</i>linical Remission Rheumatoid Ar<i>T</i>hritis (<i>RA</i>) patients (PREDICTRA)Paul Emery, Gerd R Burmester, Esperanza Naredo, et al.
Annals of the Rheumatic Diseases|May 15, 2017
High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart blockAnna R Lisney, Franziska Szelinski, Karin Reiter, et al.
Pageof 34